COST EFFECTIVENESS ANALYSIS OF ALEMTUZUMAB AS A TREATMENT OPTION FOR PATIENTS WITH MULTIPLE SCLEROSIS IN GREECE

被引：1
|
作者：
Kourkoulas, N. [1 ]
Athanasakis, K. [1 ]
Kyriopoulos, J. [1 ]
机构：
[1] Natl Sch Publ Hlth, Athens, Greece
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2025
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND59
引用
收藏
页码：S339 / S339
页数：1
相关论文
共 50 条
  • [21] THE COST-EFFECTIVENESS OF ALEMTUZUMAB IN THE MANAGEMENT OF RELAPSE-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Stanisic, S.
    Bertolotto, A.
    Berto, P.
    Di Procolo, P.
    Morawski, J.
    VALUE IN HEALTH, 2018, 21 : S338 - S338
  • [22] The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy
    Stanisic, Sanja
    Bertolotto, Antonio
    Berto, Patrizia
    Di Procolo, Paolo
    Morawski, Julia
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2019,
  • [23] Sleep and fatigue features in multiple sclerosis patients on alemtuzumab treatment
    Barun, B.
    Skoric, M. Krbot
    Mioc, M.
    Crnosija, L.
    Adamec, I.
    Mudrovcic, M.
    Milosevic, N.
    Habek, M.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 942 - 942
  • [24] Comparison of Two Treatment Schedules with Alemtuzumab in Patients with Multiple Sclerosis
    von Wussow, Peter
    Schreiber, Martin
    NEUROLOGY, 2016, 86
  • [25] Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis
    Ayati, Nayyereh
    Taheri, Saeed
    Sahraian, Mohammad Ali
    Nikfar, Shekoufeh
    CURRENT JOURNAL OF NEUROLOGY, 2021, 20 (03): : 154 - 161
  • [26] THE COST EFFECTIVENESS OF FINGOLIMOD FOR THE TREATMENT MULTIPLE SCLEROSIS IN KOREA
    Lee, J.
    Ko, S.
    VALUE IN HEALTH, 2017, 20 (09) : A724 - A724
  • [27] COST EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE VERSUS TERIFLUNOMIDE FOR THE TREATMENT OF MULTIPLE SCLEROSIS
    Ruiz, L.
    Machado, L.
    Toro-Diaz, H.
    Cele, C.
    Hernandez, L.
    Harrington, A.
    VALUE IN HEALTH, 2017, 20 (09) : A724 - A724
  • [28] A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany
    Flachenecker, Peter
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (03) : 15 - 19
  • [29] Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients
    Wang, Li
    Qi, Chun-Hui
    Zhong, Ren
    Yuan, Chao
    Zhong, Qiu-Yue
    MEDICINE, 2018, 97 (08)
  • [30] Sarcoidosis following alemtuzumab treatment for multiple sclerosis
    Willis, Mark D.
    Hope-Gill, Ben
    Flood-Page, Patrick
    Joseph, Fady
    Needham, Ed
    Jones, Joanne
    Coles, Alasdair
    Robertson, Neil P.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (13) : 1779 - 1782
12345